What Temporary Scheduling Is
Under normal circumstances, adding a substance to the federal list of controlled substances requires formal rulemaking: a proposed rule, a public comment period, and often a hearing process that can take months or years. The Controlled Substances Act includes a separate, faster track for situations the DEA considers urgent. Under 21 U.S.C. ยง 811(h), the Attorney General, acting through the DEA Administrator, can place a substance into Schedule I for up to two years if the agency finds doing so is “necessary to avoid an imminent hazard to public safety.”
That standard is not simply a judgment call. The statute requires the agency to weigh three specific factors: the substance’s history and current pattern of abuse, the scope, duration, and significance of that abuse, and the risk the substance poses to public health. In its July 2026 notices covering mitragynine pseudoindoxyl and two related compounds known as MGM-15 and MGM-16, the DEA cited their recent commercial emergence, distribution through national e-commerce channels, and their pharmacological activity as opioid receptor agonists as the basis for meeting that standard.
Why the Comment Period and Court Review Work Differently
One of the more consequential legal distinctions in this process is procedural. Ordinary federal rulemaking is governed by the Administrative Procedure Act, which generally requires agencies to publish a proposed rule, accept public comments, and respond to significant concerns before finalizing it. Temporary scheduling under the CSA is explicitly exempted from that requirement. The DEA’s Federal Register notice states plainly that “the notice-and-comment requirements of the APA…do not apply to this notice of intent.”
The same is true of judicial review. Once a temporary scheduling order takes effect, it generally cannot be challenged in court the way a permanent scheduling rule can. The Federal Register notice specifies that “temporary scheduling orders are not subject to judicial review,” while permanent scheduling actions, which follow the standard rulemaking process, can be challenged under a separate section of the CSA. In practice, this means a substance can be placed in the most restrictive federal drug category for up to two years without the opportunity for the kind of public input or court challenge that would normally accompany such a significant legal change.
Four Compounds, Two Different Exemptions
The DEA’s July 2026 action actually covers two separate notices, and this is where the distinction Kratom Science flagged becomes relevant. The first notice addresses 7-hydroxymitragynine (7-OH) and states that botanical kratom products containing only naturally occurring, trace-level amounts of 7-OH would fall outside the new restriction. In other words, whole leaf kratom that happens to contain the small amounts of 7-OH it naturally produces is not swept into the rule.
The second notice, covering mitragynine pseudoindoxyl, MGM-15, and MGM-16, does not include that same carve-out. According to the Kratom Science report, this matters because mitragynine pseudoindoxyl is not exclusively a lab-synthesized compound. It can also form naturally through oxidation as kratom leaf is stored and dried over time, meaning a product made entirely from unprocessed leaf could, in theory, contain trace amounts of a substance now facing the same scheduling treatment as concentrated 7-OH extracts, without the exemption language that protects trace natural 7-OH. The American Kratom Association, an industry advocacy group, publicly asked the agency to address this gap in early August 2026.
This Isn’t the DEA’s First Attempt
The current action is not the first time the DEA has moved toward scheduling kratom-related substances. In 2016, the agency issued a notice of intent to place kratom itself, meaning mitragynine and 7-OH broadly, into Schedule I, only to withdraw that notice after public comment and pushback from members of Congress. That episode is part of why the current approach looks different: rather than targeting kratom leaf itself, the 2026 notices are narrowly written around specific concentrated or chemically modified compounds, with natural leaf explicitly carved out of at least one of the two notices. Whether that narrower approach avoids the kind of opposition that derailed the 2016 attempt is likely to become clearer as the two-year temporary period unfolds and any move toward permanent scheduling begins.
What Happens Next
A temporary scheduling order under this authority lasts up to two years, with the possibility of a one-year extension, during which federal agencies typically continue gathering data relevant to a decision on permanent scheduling. Permanent scheduling, unlike the temporary order, would go through the full rulemaking process, including public comment and the possibility of judicial review, giving affected consumers, retailers, and researchers a more conventional avenue to weigh in or challenge the outcome.
For now, the practical legal reality is that the temporary order can take effect on its stated date without further public process, and the specific chemical thresholds and exemptions written into each notice determine which products are affected. That is why the difference between the 7-OH notice’s trace-amount exemption and the mitragynine pseudoindoxyl notice’s lack of one is not a minor technicality. It is, at least as the law is currently written, the line between a product remaining outside a Schedule I restriction and falling within one.
Why This Distinction Matters for Consumers and Retailers
Understanding the difference between temporary and permanent scheduling, and between substances with and without natural-trace exemptions, gives consumers and retailers a clearer picture of what a headline like “DEA schedules kratom compound” actually means in practice. It does not mean that whole leaf kratom itself has been placed in Schedule I. It means that specific, narrowly defined compounds, evaluated under a specific legal standard and a specific procedural track, have been temporarily restricted, with the exact boundaries of that restriction depending on definitions and exemptions written into each individual notice. Following those definitions, rather than general headlines, remains the most reliable way to understand what has and has not changed under federal law.